Advertising OptionsResources Page Advertising Links or banners on the XpressPress.com "Resources" page ensure that your message will reach more than 5,000 unique visitors per month. Contact us for rates and more information. PR Pi Blog Advertising Links or banners on the XpressPress.com blog "PR Pi" reach more than 1,000 readers who have opted in to receive the latest updates. Advertisers may choose from three sizes: a 336 x 280 large rectangle, a 300 x 250 medium rectangle, or a 160x600 wide skyscraper. Smaller format 125 x 125 rectangles are also available as are links ads which include text plus a link to your designated page. Availability is limited. Newsletter Advertising Textimonials (in-line testimonial advertising) in XpressPress.com newsletters and special mailings reach more than 1,500 readers who have opted-in to receive news updates and promotional information from Xpress Press. Advertisers running email textimonials may supply up to 150 words plus an email address and a link. Text for your ad may be supplied pending approval by our staff, or we can write copy on behalf of your product or service (for an additional charge) for inclusion in our mailing. Contact: Tina Koenig XpressPress.com 800-713-7701 954-989-3338
Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States, according to research presented at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
The use of statins has been shown to significantly decrease risk of death among patients with alcoholic cirrhosis, according to research p
The prevalence of nonalcoholic steatohepatitis (NASH), a progressive type of fatty liver disease, appears to be on the rise in adolescents, increasing four-fold between 1988 and 2010, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication.
First-degree relatives of people with non-alcoholic fatty liver disease cirrhosis have a 12 times higher risk of developing the disease when compared to those with no family history, according to research presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases.